Compare OUST & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OUST | EVO |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | OUST | EVO |
|---|---|---|
| Price | $24.98 | $3.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $34.80 | $7.00 |
| AVG Volume (30 Days) | ★ 1.9M | 66.9K |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $137,298,000.00 | ★ $887,396,457.00 |
| Revenue This Year | $35.72 | N/A |
| Revenue Next Year | $35.65 | $8.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.20 | N/A |
| 52 Week Low | $6.34 | $2.84 |
| 52 Week High | $41.65 | $4.80 |
| Indicator | OUST | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 58.06 |
| Support Level | $23.53 | $3.39 |
| Resistance Level | $28.08 | $3.63 |
| Average True Range (ATR) | 1.95 | 0.09 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 17.92 | 66.23 |
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.